The use of radioisotopes for palliation of metastatic bone pain

Journal of B.U.ON.

Volumn 13, Issue 2, 2008, Pages 177-183

  Gkialas, Ioannis ^a   Iordanidou, L ^b   Galanakis, I ^a   Giannopoulos, S ^a  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

Author keywords

Bone pain; Osseous metastases; Radiopharmaceutical therapy

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; DOXORUBICIN; ETIDRONIC ACID RE 186; LEXIDRONAM SAMARIUM SM 153; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PHOSPHORUS 32; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; SAMARIUM 153; STRONTIUM 89;

ADVANCED CANCER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG HALF LIFE; DRUG INDICATION; ERYTHROCYTE COUNT; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE COST; HEMATOLOGIC DISEASE; HUMAN; LEUKOCYTE COUNT; PROSTATE CANCER; REVIEW; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

BONE NEOPLASMS; HUMANS; NEOPLASMS; PAIN; PALLIATIVE CARE; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 45249114194     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics, 1998. CA Cancer J Clin 1998; 48: 6-29.
2. Parfitt AM. Bone remodeling, normal and abnormal: a biological basis for the understanding of cancer-related bone disease and its treatment. Cancer J Oncol 1995; 5 (Suppl 1): 1-10.
3. Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem 1999; 45: 1353-1358.
4. Choong PF. The molecular basis of skeletal metastasis. Clin Orthop 2003; 415 (Suppl): S19 (abstr).
5. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593.
6. Gunthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
7. Behrens J, Frixen U, Schipper J, Weidner M, Birchmeier W. Cell adhesion in invasion and metastasis. Semin Cell Biol 1992; 3: 169-178.
8. Li Y, Bhargava MM, Joseph A, Jin L, Rosen EM, Goldberg ID. Effect of hepatocyte growth factor/scatter factor and other growth factors on motility and morphology of non-tumorigenic and tumor cells. In Vitro Cell Dev Biol Anim 1994; 30A: 105-110.
9. Muir GH, Butta A, Shearer RJ et al. Induction of transforming growth factor beta in hormonally treated human prostate cancer. Br J Cancer 1994; 69: 130-134.
10. Fong CJ, Sherwood ER, Braun EJ Berg CA, Lee C, Kozlowski JM.. Regulation of prostatic carcinoma cell proliferation and secretory activity by extracellular matrix and stromal secretions. Prostate 1992; 21: 121-131.
11. Honore P, Rogers SD, Schwei MJ et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000; 98: 585-598.
12. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. Molecular mechanisms of cancer pain. Nat Rev Cancer 2002; 2: 201-209.
13. Nielsen OS, Munroe AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991; 9: 509-524.
14. Bullough PG (Ed). Atlas of orthopedic pathology with clinical and radiologic correlations (2nd edn). Gower Medical Publ, New York, 1992, pp 6, 17-29.
15. Abeloff M (Ed): Clinical Oncology (3rd edn). Churchill Livingston, 2004.
16. Schramel FV, Parr LF, Ghurani S, Silverman ED. Autopsy of a cadaver containing strontium-89-chloride. J Nucl Med 1997; 38: 380-382.
17. Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001; 42: 895-906.
18. ICRP publication 30, part 1, pp 35-461. Pergamon Press. Ann ICRP, Vol 2 (3-4), 1979.
19. Robinson RG, Blake GM, Preston DF et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989; 9: 271-281.
20. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986; 12: 447-454.
21. Oosterhof G, Roberts JT, de Reijke TM et al. Strontium-89 chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organization for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003; 44: 519-526.
22. 186ReHEDP in breast cancer patients. Breast Cancer Res Treat 2001; 66: 101-109.
23. Turner SL, Gruenewald S, Sptry N, Gebski V. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 2001; 84: 297-302.
24. Laing AH, Ackery DM, Bayly RJ et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991; 64: 816-822.
25. Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium-89 therapy for the palliation of pain due to osseous metastases. JAMA 1995; 274: 420-424.
26. Fuster D, Herranz R, Alcover J et al. Treatment of metastatic bone pain with repeated doses of strontium-89 in patients with prostate neoplasm. Rev Esp Med Nucl 2000; 19: 270-274.
27. Porter AT, McEwan AJB, Powe JE et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine-resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-813.
28. Quilty PM, Kirk D, Bolger JJ et al. A comparison of the palliation effects of strontium 89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40.
29. Sciuto R, Maini CL, Tofani A, Fiumara C, Scelsa M, Broccatelli M. Radiosensitization with low dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Comm 1996; 17: 799-804.
30. Mertens WC, Stitt L, Porter AT. Strontium-89 therapy and relief of pain in patients with prostate carcinoma metastatic to bone: a dose response relationship? Am J Clin Oncol 1993; 16: 238-242.
31. Bolger JJ. Strontium-89 vs. external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: Report of a multicentre trial. Semin Oncol 1993; 20 (Suppl 3): 32-33.
32. Tu S, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase III trial. Lancet 2001; 357: 336-341.
33. Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993; 34: 1031-1036.
34. Singh A, Holmes RA, Farhanghi M. Human pharmacokinetics of Samarium-153-EDTMP in metastatic cancer. J Nucl Med 1989; 30: 1814-1818.
35. Olea E, Riccabona G, Tian J. Efficacy and toxicity of Sm-153-EDTMP in the palliative treatment of skeletal metastases: results of an IAEA international multicenter study. J Nucl Med 2000; 41 (Suppl): 16 (abstr).
36. Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDTMP: pharmacokinetics, toxicity and pain response using an escalating dose schedule in the treatment of metastatic bone cancer. J Nucl Med 1992; 33: 1451-1458.
37. Sartor O, Reid RH, Hoskin PJ et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63: 940-945.
38. Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using Samarium-153 lexidronam: a double blind placebo controlled clinical trial. J Clin Oncol 1998; 16: 1574-1581.
39. de Klerk JM, Van het Schip AD, Zonnenberg BA et al. Phase I study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. J Nucl Med 1996; 37: 244-249.
40. Graham MC, Scher HI, Liu GB et al. Rhenium-186-labeled hydroxyethylidene biphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. Clin Cancer Res 1999; 5: 1307-1318.
41. Dafermou A, Colamussi P, Ciganti M, Cittanti C, Bestagno M, Piffanelli A. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001: 28: 788-798.
42. Li S, Liu J, Zhang H, Tian M, Wang J, Zheng X. Rhenium-186HEDP to treat painful bone metastases. Clin Nucl Med 2001; 26: 919-922.